HC Wainwright Issues Pessimistic Forecast for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Zevra Therapeutics in a research report issued on Wednesday, November 20th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of ($1.92) per share for the year, down from their prior estimate of ($1.74). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.77 EPS and FY2027 earnings at $1.86 EPS.

A number of other equities research analysts also recently commented on ZVRA. Canaccord Genuity Group decreased their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Roth Mkm raised their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Maxim Group upped their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Finally, JMP Securities started coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Stock Up 1.8 %

ZVRA opened at $9.13 on Friday. The company has a market capitalization of $487.36 million, a PE ratio of -4.69 and a beta of 1.93. The firm has a 50-day simple moving average of $8.12 and a two-hundred day simple moving average of $6.59. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.30.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter in the prior year, the company posted ($0.40) EPS.

Institutional Trading of Zevra Therapeutics

Institutional investors have recently bought and sold shares of the stock. Sanctuary Advisors LLC purchased a new stake in shares of Zevra Therapeutics in the second quarter valued at $474,000. Jacobs Levy Equity Management Inc. lifted its stake in Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after purchasing an additional 17,557 shares during the last quarter. Simplify Asset Management Inc. purchased a new position in shares of Zevra Therapeutics during the third quarter valued at approximately $833,000. Price T Rowe Associates Inc. MD bought a new position in shares of Zevra Therapeutics during the first quarter valued at approximately $64,000. Finally, Vanguard Group Inc. raised its holdings in shares of Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after buying an additional 58,866 shares during the period. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.